Optimized Novel Wireless Assessment of Respiratory and Circulatory Dirstress - Alarm Validation (ONWARD - AV)
Validation of the Accuracy and Relevance of Continuous Vital Sign Monitoring Using an AI-algorithm in Hospitalized Patients
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The ONWARD study evaluates user experiences from continuous vital sign monitoring alarms sent to the clinical staff in case of deviating vital signs at the general hospital ward. User experiences are evaluated though a 5-point likert questionnaire.
The study will focus on adult, hospitalized patients who are monitored at the general hospital ward with continuous, real-time vital sign monitoring combined with the WARD-CSS (WARD clinical support system) that relays alerts to the clinical staff in case of significant deviations. The evaluation focus on the user perceived relevance and usefulness of the alerts generated by the system which includes a proprietary novel alerts logic. Specifically, investigators aim to assess how users evaluate the clinical relevance of triggered change-based alerts and the helpfulness of the accompanying alert descriptions.
During monitoring, the app will be used according to the intended use and additionally two questions will be prompted if alerts are sent.
Patients monitored will have an expected length of stay at the hospital, which supports at least one day of continuous monitoring. Readings from the WARD-CSS is not blinded for treating staff to get feedback on the use of the application. This study will include up to 100 patients.
An alerting feedback questionnaire will be constructed as simple feedback buttons/sliders, prompted after an alert is 'accepted' in the app. The feedback buttons will only be prompted for a representative proportion of the alerts. This will be done at random based on the alert frequencies determined in the retrospective analysis. This way, a close to equal amount of feedback responses will be prompted and obtained for different alert types with different occurrences. The feedback will be linked to the alert in the app, such that feedback can be submitted at any point in time, thus not disturbing the nurse while medical intervention is provided.
The feedback will be constructed with the following two interactions for the clinical staff.
- Alert relevance in relation to deterioration of the patient (5-point Likert scale).
- Relevance of the description following alerts in relation to the helpfulness in the patient assessment/care (5-point Likert scale)
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Eske K Aasvang, DMSci
- Telefonnummer: +4526232076
- E-Mail: Eske.Kvanner.Aasvang.01@regionh.dk
Studieren Sie die Kontaktsicherung
- Name: Aslak B Johansen, M.D.
- Telefonnummer: +4522952551
- E-Mail: aslak.broby.johansen@regionh.dk
Studienorte
-
-
-
Copenhagen, Dänemark, 2100
- Rigshospitalet
-
Copenhagen, Dänemark, 2400
- Bispebjerg Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion criteria:
Patients can be included if they meet all the following criteria:
- Age ≥ 18 years
- Patients assessed by the clinical staff as having an acute condition with risk for clinical deterioration.
- Expected admission for more than 24 hours to a general ward.
Exclusion criteria:
Patients are excluded if they meet any of the following criteria:
- Having implanted electronic devices (such as pacemaker or Implantable Cardioverter Defibrillator (ICD) device).
- Known pregnancy or breastfeeding
- Inability to give informed consent.
- The participant expected not to cooperate with study procedures.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Adult, hospitalized patients who are monitored for vital signs in the general wards
|
The intervention involves continuous, real-time vital sign monitoring using sensors to measure vital signs combined with WARD-CSS and novel algorithms designed to detect clinically relevant deviations in the vital signs.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Relevance of alerts
Zeitfenster: Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
|
The staff evaluated relevance of alerts triggered during continuous vital signs monitoring Evaluated by 5-point Likert scale: 1. Not relevant 2 Slightly relevant 3 Moderately relevant 4 Relevant 5 Highly Relevant |
Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Relevance of the description
Zeitfenster: Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
|
Relevance of the description following alerts in relation to the helpfulness in the patient assessment/care Evaluated by 5-point Likert scale:
4 Agree 5 Strongly Agree |
Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Alert rate
Zeitfenster: Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
|
Total alert rate, including false alert rate, of the WARD-CSS.
|
Start of monitoring after enrollment with informed consent. An expected minimum of 24 hours of monitoring up to 7 days after start of monitoring.
|
|
Postoperative complications
Zeitfenster: 30 days
|
Postoperative complications, defined by internationally agreed criteria
|
30 days
|
|
Heart rate (measured in beats per minute (BPM))
Zeitfenster: 7 days
|
Collected continuously
|
7 days
|
|
SpO2 (blood oxygen saturation, measured in percentage)
Zeitfenster: 7 days
|
Collected continuously
|
7 days
|
|
Blood pressure (measured in mmHg)
Zeitfenster: 7 days
|
Collected continuously
|
7 days
|
|
Respiration Rate (measured in BrPM)
Zeitfenster: 7 days
|
Collected continuously
|
7 days
|
|
Pulse (measured in BPM)
Zeitfenster: 7 days
|
Peripheral pulse - Collected continuously
|
7 days
|
|
Temperature (measured in degrees Celcius)
Zeitfenster: 7 days
|
Collected continuously
|
7 days
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2502107 (MREC)
- 2025071987 (Andere Kennung: DMA)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Postoperative Versorgung
-
The Affiliated Hospital of Xuzhou Medical UniversityRekrutierungCLL | SLL | CAR-T-ZelltherapieChina
-
Xuzhou Medical UniversityNoch keine RekrutierungNicht-invasive CAR-T-Zellüberwachung | BCMA-gerichtete PET-Bildgebung | CAR-T-Zell-Biodistribution und -Persistenz | GMP-konforme Radiopharmazeutische Zubereitung
-
Duke UniversityNational Institutes of Health (NIH)RekrutierungTransplantation hämatopoetischer Stammzellen | CAR-T-ZelltherapieVereinigte Staaten
-
Patrick C. Johnson, MDRekrutierung
-
The Lymphoma Academic Research OrganisationBristol-Myers Squibb; Novartis; Gilead SciencesRekrutierungHämatopathologie-geeignet oder CAR-t-ZellbehandlungFrankreich
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRekrutierungKomplikationen der CAR-T-TherapieItalien
-
University Health Network, TorontoRekrutierungLymphom, das eine CAR-T-Therapie erhältKanada
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRekrutierungVom Patienten gemeldete Ergebnismessungen | CAR-T-Zell-TherapieSchweiz
-
Ruijin HospitalAktiv, nicht rekrutierendALL (akute B-lymphoblastische Leukämie) | CAR-T-ZelltherapieChina
-
Shanghai International Medical CenterUnbekanntFortgeschrittener solider Tumor | PD-1-Antikörper | CAR-T-ZellenChina
Klinische Studien zur Continuous vital sign monitoring
-
Hamilton Health Sciences CorporationMcMaster University; Population Health Research Institute; Cloud DX Inc.Noch keine Rekrutierung
-
Sunnybrook Health Sciences CentreAlzheimer Society of CanadaRekrutierung
-
University Hospital, Basel, SwitzerlandClinical Trial Unit, University Hospital Basel, SwitzerlandAbgeschlossen
-
KOS Inc.Noch keine RekrutierungDiabetes mellitus, Typ 2 | Diabetes | Prädiabetes | Diabetes mellitus, Typ-1-DiabetesVereinigte Staaten
-
Hospital Universitario San IgnacioPontificia Universidad JaverianaNoch keine Rekrutierung
-
Darma Inc.Virginia Commonwealth UniversityAbgeschlossenÜberwachung der VitalfunktionenVereinigte Staaten
-
Linshom Medical, Inc.University of Maryland, Baltimore; Maryland Industrial PartnershipsRekrutierungAtemwegskomplikation | Postoperatives AtemversagenVereinigte Staaten
-
Linshom Medical, Inc.National Heart, Lung, and Blood Institute (NHLBI); Ohio State UniversityRekrutierungAtemwegskomplikation | Postoperatives AtemversagenVereinigte Staaten
-
Emory UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)AbgeschlossenTyp 2 Diabetes | Nierenerkrankung im EndstadiumVereinigte Staaten
-
SinocareArcher ResearchAnmeldung auf EinladungDiabetes Mellitus | System zur kontinuierlichen GlukoseüberwachungBelgien